Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | EGLN1 | Q9GZT9 | 3/20 | 0.33 |
| ▸ | CCR2 | P41597 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | RORC | P51449 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | GSK3B | P49841 | 1/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6669028 | 0.88 | MAPK1 (0.39) | MAPK1GAAALDH1A1KMT2AMAPT | |
| SCHEMBL6668056 | 0.88 | MAPK1 (0.39) | MAPK1GAAALDH1A1KMT2AMAPT | |
| SCHEMBL6672693 | 0.87 | MAPK1 (0.38) | MAPK1GAAALDH1A1KMT2AMAPT | |
| SCHEMBL6671395 | 0.85 | ALDH1A1 (0.44) | MAPK1ALDH1A1KMT2ATHRB | |
| SCHEMBL6669314 | 0.85 | KCNH2 (0.46) | ALDH1A1MAPTKCNH2 | |
| SCHEMBL6669974 | 0.84 | MAPK1 (0.37) | MAPK1GAAALDH1A1KMT2AMAPT | |
| SCHEMBL6667440 | 0.83 | MAPK1 (0.35) | MAPK1GAAALDH1A1KMT2AMAPT | |
| SCHEMBL6672226 | 0.82 | MAPK1 (0.36) | MAPK1ALDH1A1KMT2A | |
| SCHEMBL6667328 | 0.82 | MAPK1 (0.37) | MAPK1GAAALDH1A1KMT2AMAPT | |
| SCHEMBL6670932 | 0.81 | MAPK1 (0.41) | MAPK1GAAALDH1A1KMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2004019940-A1 | METHOD OF PREVENTING OR TREATING ATHEROSCLEROSIS OR RESTENOSIS | PHARMACIA & UPJOHN COMPANY (US) | 2004-03-11 | — | — | WO | claimed |
| EP-1265872-A1 | 4-HYDROXYCINNOLINE-3-CARBOXYAMIDES AS ANTIVIRAL AGENTS | PHARMACIA & UPJOHN COMPANY (US) | 2002-12-18 | — | — | EP | claimed |
| WO-2001081318-A1 | 4-HYDROXYCINNOLINE-3-CARBOXYAMIDES AS ANTIVIRAL AGENTS | PHARMACIA & UPJOHN COMPANY (US) | 2001-11-01 | — | — | WO | claimed |
| WO-2004019940-A1 | METHOD OF PREVENTING OR TREATING ATHEROSCLEROSIS OR RESTENOSIS | PHARMACIA & UPJOHN COMPANY (US) | 2004-03-11 | — | — | WO | disclosed |
| EP-1265872-A1 | 4-HYDROXYCINNOLINE-3-CARBOXYAMIDES AS ANTIVIRAL AGENTS | PHARMACIA & UPJOHN COMPANY (US) | 2002-12-18 | — | — | EP | disclosed |
| WO-2001081318-A1 | 4-HYDROXYCINNOLINE-3-CARBOXYAMIDES AS ANTIVIRAL AGENTS | PHARMACIA & UPJOHN COMPANY (US) | 2001-11-01 | — | — | WO | disclosed |